Literature DB >> 2646258

Tumor temperature distributions predict hyperthermia effect.

J R Oleson1, M W Dewhirst, J M Harrelson, K A Leopold, T V Samulski, C Y Tso.   

Abstract

Review of clinical hyperthermia (HT) trial results shows that there previously has not been a robust model relating efficacy of HT treatments to characteristics of the temperature distribution. Lack of a model has been an impediment in Phase II trials; these trials must include defining the prescription for HT treatment, optimizing the schedule of HT treatments, and defining quality assurance procedures. We propose a model that is based upon noting that the majority of a tumor volume is contained in the outermost "shell" of a solid tumor, across which shell the radial temperature distribution is assumed to be linear. Any linear distribution can be defined by coordinates of a point and a slope, and we choose the temperature at the radiographically defined edge of a tumor and the slope (dT/dr) across the outer shell as these determinants of the linear radial temperature distribution. A discriminant analysis of success or failure of treatment can then be based upon these two descriptors (Tedge, dT/dr). We have tested this model using data from patients with soft tissue sarcoma (Stage IIB or greater) that have entered an ongoing prospective trial of conventional preoperative radiotherapy (5000 cGy/25 Fx/5 wk) together with HT, the latter randomized to be given once or twice weekly during the 5 week course. Wide local excision of the primary tumor is done 1 month after completion of radiotherapy, and the extent of histologic change in the resected specimen is scored. Our model has an 86% predictive value for lack of complete or nearly complete necrosis in the resected specimen according to whether the time-averaged Tedge and slope during each HT treatment satisfy the equation Tedge + 1.2 (slope in degree C/cm) less than or equal to 40.6 degrees C in all but one treatment at most. Conversely, in 85% of cases with complete or nearly complete tumor necrosis, temperature distributions satisfied Tedge + 1.2 (slope in degree C/cm) greater than 40.6 degrees C during at least one HT treatment. Requiring greater than or equal to one third of treatments of a patient to satisfy the preceeding discriminant equation resulted in 80% of patients being correctly classified as a responder or nonresponder, with only one false positive prediction (patient incorrectly classified as a responder). The model can reveal systematic changes in the edge temperature distribution during the treatment course that are consistent with tumor perfusion changes inferred and measured by independent means.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2646258     DOI: 10.1016/0360-3016(89)90472-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.

Authors:  R J Griffin; S H Lee; K L Rood; M J Stewart; J C Lyons; Y S Lew; H Park; C W Song
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

Review 2.  Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer.

Authors:  Eduardo G Moros; Jose Peñagaricano; Petr Novàk; William L Straube; Robert J Myerson
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 3.  Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial.

Authors:  B Rau; P Wust; P Hohenberger; J Löffel; M Hünerbein; C Below; J Gellermann; A Speidel; T Vogl; H Riess; R Felix; P M Schlag
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

4.  [Phase II study on preoperative radio-chemo-thermotherapy in locally advanced rectal carcinoma].

Authors:  B Rau; P Wust; J Gellermann; W Tilly; M Hünerbein; J Löffel; H Stahl; H Riess; V Budach; R Felix; P Schlag
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

5.  Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients.

Authors:  R D Issels; J Mittermüller; A Gerl; W Simon; A Ortmaier; C Denzlinger; H Sauer; W Wilmanns
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Vascularized tissue transfer for closure of irradiated wounds after soft tissue sarcoma resection.

Authors:  W J Barwick; J A Goldberg; S P Scully; J M Harrelson
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

7.  PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts.

Authors:  J J Parry; V Sharma; R Andrews; E G Moros; D Piwnica-Worms; B E Rogers
Journal:  Cancer Gene Ther       Date:  2008-08-29       Impact factor: 5.987

8.  Study of tumor growth under hyperthermia condition.

Authors:  Qing Zhu; Aili Zhang; Ping Liu; Lisa X Xu
Journal:  Comput Math Methods Med       Date:  2012-09-03       Impact factor: 2.238

9.  Magnetic Heating Stimulated Cargo Release with Dose Control using Multifunctional MR and Thermosensitive Liposome.

Authors:  Sayoni Ray; Chi-An Cheng; Wei Chen; Zhao Li; Jeffrey I Zink; Yung-Ya Lin
Journal:  Nanotheranostics       Date:  2019-04-19

10.  High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area.

Authors:  Susanne Kossatz; Robert Ludwig; Heidi Dähring; Volker Ettelt; Gabriella Rimkus; Marzia Marciello; Gorka Salas; Vijay Patel; Francisco J Teran; Ingrid Hilger
Journal:  Pharm Res       Date:  2014-06-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.